Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Mirum Pharmaceuticals (NASDAQ:MIRM) released its earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22), Zacks reports. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%.

Mirum Pharmaceuticals Trading Up 1.2 %

MIRM traded up $0.59 during mid-day trading on Wednesday, hitting $50.52. 486,456 shares of the stock were exchanged, compared to its average volume of 528,812. The firm’s fifty day moving average is $46.52 and its two-hundred day moving average is $43.27. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $54.23. The company has a market cap of $2.43 billion, a PE ratio of -25.01 and a beta of 0.96. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Robert W. Baird boosted their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $57.10.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 2,627 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the transaction, the chief operating officer now owns 26,961 shares of the company’s stock, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now owns 119,359 shares of the company’s stock, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,915 shares of company stock valued at $1,897,920 in the last three months. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.